eligibility_summary
Eligible: histologically confirmed, untreated esophageal squamous cell carcinoma, KPS ≥70, NRS-2002 ≥2, adequate marrow/organ function (Hb ≥100 g/L, ANC ≥1.5×10^9/L, PLT ≥100×10^9/L, WBC ≥3.5×10^9/L, ALT/AST ≤1.5×ULN, TBIL ≤1.5×ULN, Cr ≤1.5×ULN, BUN ≤ULN). Exclude: prior therapy, other active malignancy (except cured basal cell skin/cervical CIS), distant mets beyond supraclavicular nodes, active infections, targeted-therapy contraindications.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in elderly/malnourished unresectable ESCC evaluates nimotuzumab with concurrent chemoradiotherapy (S-1 plus radiotherapy), followed by surgery. Drugs/interventions and mechanisms: • Nimotuzumab: humanized anti-EGFR monoclonal antibody (targeted biologic) that blocks ligand binding and EGFR activation, downregulating MAPK/ERK and PI3K/AKT signaling, inhibits proliferation, enhances radio/chemosensitivity, and can mediate ADCC. • S-1: oral fluoropyrimidine chemotherapy (tegafur/gimeracil/oteracil), a 5-FU prodrug antimetabolite that inhibits thymidylate synthase, impairing DNA synthesis. • Radiotherapy: external beam ionizing radiation causing DNA damage (DSBs). Targeted cells/pathways: EGFR-overexpressing ESCC tumor cells, proliferative/survival pathways (EGFR→MAPK/ERK, PI3K/AKT), DNA replication/repair in rapidly dividing cells.